Big Pharma At The Senate: When It Comes To Yes Or No Questions, There Are Still A Few Maybes
Our question-by-question infographic shows how Rx executives exhibited enough finesse to avoid any embarrassing sound bites at the Senate Finance Committee hearing on drug pricing.
You may also be interested in...
While neither party is likely to make any big policy changes this year, the action from both sides of the aisle indicates politicians still see going after pharma as a winning issue with voters even as polls show voters are focused elsewhere.
Broad bipartisan support and billions in projected savings mean that bill may finally pass. But whether it will work as intended to improve generic access to market remains as questionable as ever.
Recent launches by Lilly, Amgen and Gilead suggest list prices may decrease with the HHS proposal to disrupt the rebate system, but not as low as current net prices after rebates, according to pharmacy benefit experts.